O
OPX Biotechnologies
At OPXBIO, we’re in the Good Chemistry business. We develop and produce bio-based chemicals and fuels that deliver more sustainable value to our customers
About OPX Biotechnologies
OPX Biotechnologies (OPXBIO), founded in 2007, operated in the renewable chemicals sector, focusing on producing bio-based chemicals and fuels as sustainable alternatives to petroleum-based products. The company was co-founded by Ryan T. Gill, a professor in Chemical and Biological Engineering at the University of Colorado Boulder whose research focuses on metabolic engineering and synthetic biology. This academic foundation was central to OPXBIO's core competency.
The company's business model revolved around leveraging its proprietary EDGE™ (Efficiency Directed Genome Engineering) technology. This platform was designed for the rapid optimization of microbes and bioprocesses, enabling the company to develop and scale products faster than conventional methods. OPXBIO's primary clients were large chemical companies seeking to integrate renewable materials into their existing supply chains. Its main product was BioAcrylic, a bio-based acrylic acid produced via fermentation of sugars. This product was developed as a direct, performance-equivalent replacement for petro-acrylic, which is used in a multi-billion dollar global market for applications like paints, adhesives, diapers, and detergents. Another key development was a process to produce fatty acids from syngas or sugar feedstocks, which could be converted into renewable chemicals and fuels like diesel and jet fuel.
A significant milestone was a joint development agreement with The Dow Chemical Company to scale up the BioAcrylic production process. The company also received a $6 million award from the U.S. Department of Energy's ARPA-E program to support its fatty acid research. After raising significant venture capital from investors including Mohr Davidow Ventures, US Renewables Group, and Braemar Energy Ventures, OPX Biotechnologies demonstrated its BioAcrylic production at a large, 3,000-liter demonstration scale. The company's trajectory culminated in April 2015, when its fermentation-based processes and systems were acquired by agricultural giant Cargill. The acquisition was seen as a strategic move for Cargill to expand its presence in commercial fermentation products for non-food applications. Following a transition period, OPX Biotechnologies was wound down.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for OPX Biotechnologies is 290 monthly website visits. OPX Biotechnologies's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
OPX Biotechnologies in its local ecosystem
The OPX Biotechnologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Xseed Capital
ARPA-E
Series A3 investors entered at this stage
Mohr Davidow Ventures
Braemar Energy Ventures
Altira
Series B and later2 investors entered at this stage
US Renewables Group
DBL Partners
Other known investors1 additional known investor
Cargill
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about OPX Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OPX Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








